Ventyx Biosciences Inc (NASDAQ:VTYX) — Market Cap & Net Worth
Market Cap & Net Worth: Ventyx Biosciences Inc (VTYX)
Ventyx Biosciences Inc (NASDAQ:VTYX) has a market capitalization of $1.00 Billion ($1.00 Billion) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #8891 globally and #2528 in its home market, demonstrating a 0.29% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Ventyx Biosciences Inc's stock price $14.00 by its total outstanding shares 71750148 (71.75 Million). Also see how large is Ventyx Biosciences Inc's balance sheet for a full breakdown of the balance sheet.
Ventyx Biosciences Inc Market Cap History: 2021 to 2026
Ventyx Biosciences Inc's market capitalization history from 2021 to 2026. Data shows change from $1.42 Billion to $1.00 Billion (-8.87% CAGR). Also see VTYX cash generation efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Ventyx Biosciences Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.04% | #255 of 976 |
|
NASDAQ Composite
IXIC
|
$41.69 Trillion | 0.00% | #946 of 3165 |
Weight: Ventyx Biosciences Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Ventyx Biosciences Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Ventyx Biosciences Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Ventyx Biosciences Inc (VTYX) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of VTYX by Market Capitalization
Companies near Ventyx Biosciences Inc in the global market cap rankings as of September 18, 2026. Review Ventyx Biosciences Inc (VTYX) tangible equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Ventyx Biosciences Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Ventyx Biosciences Inc Historical Marketcap From 2021 to 2026
Between 2021 and today, Ventyx Biosciences Inc's market cap moved from $1.42 Billion to $ 1.00 Billion, with a yearly change of -8.87%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.00 Billion | +55.04% |
| 2025 | $647.90 Million | +312.33% |
| 2024 | $157.13 Million | -11.34% |
| 2023 | $177.22 Million | -92.47% |
| 2022 | $2.35 Billion | +65.11% |
| 2021 | $1.42 Billion | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Ventyx Biosciences Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.00 Billion USD |
| MoneyControl | $1.00 Billion USD |
| MarketWatch | $1.00 Billion USD |
| marketcap.company | $1.00 Billion USD |
| Reuters | $1.00 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Ventyx Biosciences Inc
Ventyx Biosciences, Inc., a clinical-stage biopharmaceutical company, develops oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its pipeline includes small molecule therapeutics to treat inflammation across cardiometabolic disorders, neurodegenerative diseases, and inflammatory disorders. The company's portfolio of NLRP3 inhibitors includes VTX958, a sele… Read more